Esmolol
Title: Esmolol
CAS Registry Number: 81147-92-4
CAS Name: 4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzenepropanoic acid methyl ester
Additional Names: (±)-methyl 3-[4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl]propionate; methyl p-[2-hydroxy-3-(isopropylamino)propoxy]hydrocinnamate
Molecular Formula: C16H25NO4
Molecular Weight: 295.37
Percent Composition: C 65.06%, H 8.53%, N 4.74%, O 21.67%
Literature References: Cardioselective b-adrenergic blocker. Prepn: E. I. Carlsson et al., EP 41491 (1982 to A.B. Hässle), C.A. 96, 122391f (1982); P. W. Erhardt et al., EP 53435; eidem, US 4593119 (1982, 1986 both to Am. Hosp. Supply); P. W. Erhardt et al., J. Med. Chem. 25, 1408 (1982). Pharmacology: R. J. Gorczynski et al., J. Cardiovasc. Pharmacol. 5, 668 (1983); eidem, ibid. 6, 1548 (1984). Pharmacokinetics: A. Yacobi et al., J. Pharm. Sci. 72, 711 (1983). GC-MS determn in blood: C. Y. Sum, A. Yacobi, ibid. 73, 1177 (1984). Clinical studies of effect in supraventricular tachycardia: G. Klein et al., Int. J. Clin. Pharmacol. Ther. Toxicol. 22, 112 (1984); R. J. Gray et al., J. Am. Coll. Cardiol. 5, 1451 (1985). Symposium on pharmacology and clinical efficacy: Am. J. Cardiol. 56(11), 1F-62F (1985). Review of pharmacology and clinical efficacy: P. Benfield, E. M. Sorkin, Drugs 33, 392-412 (1987).
Properties: Oil, gradually forming crystalline rosettes at room temp, mp 48-50°.
Melting point: mp 48-50°
 
Derivative Type: Hydrochloride
CAS Registry Number: 81161-17-3
Manufacturers' Codes: ASL-8052
Trademarks: Brevibloc (Ohmeda)
Molecular Formula: C16H25NO4.HCl
Molecular Weight: 331.83
Percent Composition: C 57.91%, H 7.90%, N 4.22%, O 19.29%, Cl 10.68%
Properties: Crystals from methanol-ether, mp 85-86°.
Melting point: mp 85-86°
 
Therap-Cat: Antiarrhythmic.
Keywords: ?Adrenergic Blocker; Antiarrhythmic.

Others monographs:
SulfaquinoxalineExametazimeε-Acetamidocaproic AcidTanghinigenin
FucoxanthinOxycodoneHordenineVinylbital
Misch MetalHexaconazolePhenazopyridineButyl Isocyanate
DihydrotachysterolSpleninTipifarnibNorgestimate
©2016 DrugLead US FDA&EMEA